Skip to main content

Epigenica

Category: AI in Biotech / Drug Discovery

Epigenica develops high-throughput epigenetic research tools and platforms to accelerate biomarker discovery and precision medicine. Epigenica was founded in 2020. The company is led by Mohamad Takwa, PhD. Based in Solna, Stockholm, Sweden. Team size: 11-50. Total funding raised: $2.2M. Latest round: Seed. Key investors include Voima Ventures, Navigare Ventures, Leksell Social Ventures, Almi Invest.

Founded
2020
Headquarters
Solna, Stockholm, Sweden
Team size
11-50
Total funding
$2.2M

Value proposition

Enables rapid, scalable, and affordable generation of multiple genome-wide epigenetic profiles simultaneously, reducing time and cost for comprehensive epigenetic studies.

Products and solutions

EpiFinder™ Platform, EpiFinder Genome Kit (hmqChIP-seq), EpiFinder™ GenomePro, EpiFinder™ cNUC

Unique value

The platform's core innovation is its patented high-throughput, multiplex, quantitative ChIP-seq (hmqChIP-seq) technology, which allows for the simultaneous profiling of up to eight epigenetic markers across 24 samples.

Target customer

Pharmaceutical companies, biotech firms, academic research institutions, and scientists in oncology, drug discovery, and diagnostics.

Industries served

Drug Discovery & Development, Precision Medicine, Biomedical Research, Clinical Diagnostics, Longevity/Aging Research

Technology advantage

The multiplexing capability significantly increases research throughput (up to 192 profiles at once) and reduces costs compared to traditional single-marker, single-sample methods, enabling more complex and comprehensive studies.

How they differentiate

Epigenica differentiates through its high-throughput multiplexing capability, which offers greater scalability and cost-efficiency for large-scale epigenetic profiling compared to competitors who often focus on single-marker analysis.

Main competitors

Cambridge Epigenetix, EpiCypher, Active Motif

Key partnerships

Voima Ventures, NGI Stockholm (SciLifeLab) — first certified core lab and service provider for EpiFinder platform, collaborations with undisclosed pharmaceutical partners and academic institutions.

Notable customers

Engaged in pilot studies with undisclosed European pharmaceutical companies. NGI Stockholm (SciLifeLab) became first certified service provider offering EpiFinder platforms to the research community.

Major milestones

Launched its first commercial product, the EpiFinder Genome kit., Secured a patent for its core hmqChIP-seq technology., Successfully closed a $2.2 million seed funding round in June 2025., Launched EpiFinder™ GenomePro in September 2025., Launched EpiFinder™ cNUC for liquid biopsy epigenomic profiling., NGI Stockholm became first certified core lab and service provider for EpiFinder platform (May 2026).

Growth metrics

N/A

Market positioning

Positioned as an enabler of next-generation multi-omics research, providing tools for complex, large-scale studies in the premium R&D market.

Geographic focus

Primarily Europe, with plans for global expansion.

Patents and IP

The company holds a patent for its high-throughput multiplex quantitative ChIP-seq technology (hmqChIP-seq).

About Mohamad Takwa, PhD

Mohamad Takwa, PhD, is a seasoned entrepreneur and scientist with a strong background in biotechnology. He co-founded Epigenica and has been instrumental in its growth, securing significant funding and leading the development of its innovative epigenetic screening technologies. His experience spans founding and leading multiple ventures, demonstrating a strategic and visionary approach to transforming scientific research into commercial applications.

Official website: